The study was conducted to evaluate the efficacy and safety of Vigadexa(0.5 percent moxifloxacin and 0.1 percent dexamethasone) in the treatment of bacterial conjunctivitis. The results showed that before treatment, the inflamation level was mild and moderate in 118 (79.2 percent) eyes and severe in 31 (20.8 percent) eyes. Of these 31 severe eyes, 14 (9.4 percent) had pseudomembrane and 8 (5.4 percent) had superfical punctate keratitis. With treatment, complete resolution was 67.8 percent of eyes in 8 days, and 87.2 percent in 12 days. No complications were noted in all patients. In conclusion, Vigadexaeyedrop appeared to be a highly effective treatment for baterial conjunctiviiis. The eyedrops was also safe and well tolerated. The combination formulation was convenient for use, reducing cost and increasing effectiveness of treatment.
- Đăng nhập để gửi ý kiến